Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/Allisartan
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 346 participants.
Also called NCT07704697
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 346 participants
- Registry
-
NCT07704697
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT07704697. Randomized; quadruple masking; primary purpose treatment. Start 2024-11-23 (actual); primary completion 2025-11-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/Allisartan
- Condition
- Essential Hypertension
- Intervention (Drug)
- Experimental: Sacubitril/Allisartan and Amlodipine Group
- Intervention (Drug)
- Active Comparator: Sacubitril/Allisartan Group
- Lead sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Record details
- Record id
cardio:ct-nct07704697- Content hash
0e93709ee4b3d9f716fb272c164a46436e06e3174062f8de722b6add41759b0b